Pharmaceutical controversy highlights gaps in health-care regulations
A drug manufacturer downplaying an inexpensive drug and promoting a more expensive alternative highlights gaps in the drug approval process in the
“A drug company discouraging the use of one of its drugs is a very unique situation. It’s something that hasn’t happened before” says Queen’s University ophthalmology professor Rob Campbell.
Dr. Campbell is the lead author on the international study looking at policies and procedures in the
Drug companies usually cover the costs of obtaining approval from regulators including the Food and Drug Administration (FDA) and Health
The controversy involves two drugs used to treat age-related macular degeneration (AMD) – the leading cause of blindness in high-income countries.
One drug costs almost $2,000 a dose and has been approved by the FDA in the
Queen’s researcher Sudeep Gill (School of Medicine) and University of Toronto’s Irfan Dhalla and Chaim Bell also contributed to the study. Dr. Campbell is also Residency Program Director and Acting Deputy Head of Ophthalmology at Kingston General Hospital and Hotel Dieu Hospital. He also works with the Institute for Clinical Evaluative Sciences.
The study is published online today by the BMJ (British Medical Journal).